Skip to content

Evaluation of Capsulotomy by Linear Accelerator Radiosurgery in Severe and Refractory Obsessive-compulsive Disorder

Initial Evaluation of Efficacy and Adverse Events of Single Lesions in Bilateral Ventral-capsular and Ventral Capsulotomy-striatal by Linear Accelerator Radiosurgery in Severe and Refractory Obsessive-compulsive Disorder

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02500888
Enrollment
10
Registered
2015-07-17
Start date
2015-06-30
Completion date
2022-06-30
Last updated
2021-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

OCD, Quality of Life

Keywords

OCD, Neurosurgery, Radiosurgery

Brief summary

The aim of this study is to evaluate, through a pilot study with about ten cases, if bilateral ventral capsulotomy by linear accelerator enable modification of obsessive-compulsive symptoms and quality of life in patients with severe and refractory obsessive compulsive disorder (OCD) and also investigate possible adverse effects / complications of the procedure.

Detailed description

About ten patients with severe and refractory OCD will receive bilateral single lesions at the bottom of the anterior limb of the internal capsule by linear accelerator. Prior to the procedure, a detailed clinical and psychiatric evaluation, plus an extensive battery of psychiatric diagnostic tests, severity and progression of OCD, depression / anxiety symptoms, presence of tics, psychosocial impairment, quality of life, familial accommodation and neuropsychological and personality testes will be performed. Furthermore, the patients will be also assessed by serological and neuroimaging tests. The Individuals will be periodically evaluated and followed up for one year. The results of the scores of the rating scales will be analyzed and compared, as well as the profile of adverse events, cognitive or personality changes and improves in clinical tests and neuroimaging studies.

Interventions

RADIATIONRadiosurgery

Only one radiation session of about 180 Gy in bilateral internal capsule.

Sponsors

Hospital de Clinicas de Porto Alegre
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

1. OCD diagnosis, according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) as a major disease entity. If comorbidity with other psychiatric or personality disorders, OCD symptoms dominate the clinical picture and precede other disorders. 2. Duration of OCD symptoms of at least five years. 3. Scores range of the obsessive-compulsive symptoms Yale-Brown Obsessive-Compulsive Scale (YBOCS) greater than 26 (or greater than 13, if obsessions or compulsions alone). 4. Fill up the criteria for refractory to prior treatments. 5. Be accepted by the method of best estimate for defining the patient is refractory, which consisted of confirmation by at least two specialists obsessive-compulsive disorder that the patient fulfills the criteria for effective refractory to previous treatments.

Exclusion criteria

1. History of head trauma or post-traumatic amnesia. 2. Background of systemic or neurological diseases with brain impairment, severe and active. 3. History of current use of substances capable of inducing psychopathological manifestations, or signs of cumulative effects of alcohol or drugs in the central nervous system (such as cortical atrophy), confirmed by neuroimaging. 4. pregnancy or lactation. 5. Refusal to submit to the radiosurgical procedure. 6. Refusal to accept the informed consent form, or participate. 7. History of mental retardation and / or inability to understand the informed consent, confirmed by neuropsychological tests of the initial evaluation. 8. Lack of family or companion with proper capacity of understanding of the informed consent in patients with comorbid major depression or psychosis that could potentially have difficulty performing the appropriate judgment as to participate in the study.

Design outcomes

Primary

MeasureTime frameDescription
Change in OCD symptomsEvery 3 months until 12 monthsApplication of Yale-Brown Obsessive-Compulsive Scale (Y-Bocs) scale

Secondary

MeasureTime frameDescription
Change in brain-derived neurotrophic factor (BDNF) blood dosing12 monthsSerological blood tests
Change in psychological tests12 monthsApplication of: * Mini Mental Modified (3MS) test * Wechsler of intelligence test * Stroop of colors test * Tracks tests A and B * Boston Naming Test (BNT) * Wechsler Memory Scale Revised (WMS-R) * Wisconsin (WCST) test * Brief Visual Memory Test (BVLT) * Hopkins Verbal Learning Test (HBLT) test * Benton Line Orientation (BLO) test * Grooved Pegboard Test * Finger Tapping test * Complex figure of Rey test
Side effects and complicationsEvery 3 months until 12 monthsApplication of Systematic Assessment for Treatment Emergent Effects (SAFTEE) Event List and Interview.
Change in familial accommodationEvery 3 months until 12 monthsApplication of Family Accommodation Scale for Obsessive-Compulsive Disorder (FAS)
Change in anxiety symptoms.Every 3 months until 12 monthsApplication of Beck Anxiety Inventory (BAI) scale
Change in quality of life.Every 3 months until 12 monthsApplication of Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) scale
Change in near-infrared spectroscopy (NIRS) brain blood flow12 monthsDuring application of Stroop psychological test.
Change in OCD symptoms by CPRSEvery 3 monthsApplication of Comprehensive Psychopathological Rating Scale (CPRS)
Change in OCD symptoms by NIMH.Every 3 monthsApplication of National Institute of Mental Health Global Obsessive-Compulsive Scale (NIMH OCD Scale)
Change in Global FunctioningEvery 3 months until 12 monthsApplication of Global Assessment of Functioning Scale (GAF)
Change in depressive symptoms.Every 3 months until 12 monthsApplication of Beck Depression Inventory (BDI) scale

Countries

Brazil

Contacts

Primary ContactPaulo Abreu, M.D.; Ph.D.
paulo.abreu@ufrgs.br555133598294
Backup ContactMarcelo Sousa, M.D.; M.Sc
mbsousa@hcpa.edu.br555199557634

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026